Skip to content

Mescaline

A classic psychedelic phenethylamine found in several cacti and central to long-standing ceremonial traditions.

State of the evidence

Synthesized

Synthesized from 10 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Mescaline, peyote, san pedro, huachuma, then ranked by relevance.

Mescaline is a classic serotonergic psychedelic that acts primarily as a 5-HT2A receptor agonist and induces profound alterations in consciousness, emotion, and cognition. Large population studies (n > 130,000) consistently find no association between lifetime mescaline use and mental health problems or suicidal behavior, and long-term religious peyote use shows no psychological or cognitive deficits. However, clinical evidence is weak (no adequate RCTs as of 2026), and mescaline can trigger psychosis in vulnerable individuals, though the magnitude of this risk is not well quantified.

Confidence in the evidence

Moderate
  • Two large population studies (n=130,152 and n=135,095) consistently find no link between lifetime mescaline use and mental health problems, providing robust epidemiological evidence.
  • A cross-sectional study of 61 long-term peyote users found no psychological or cognitive deficits, supporting safety in a specific context.
  • No adequate RCTs on mescaline exist (as of 2026), and the clinical evidence base is described as the weakest strand, limiting causal conclusions.
  • The risk of psychosis in vulnerable individuals is acknowledged but inadequately quantified, and most studies rely on self-report or observational designs.
How we rate confidence

Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.

Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.

Evidence by study

Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.

Lifetime use of psychedelics (including mescaline) was not associated with increased mental health problems after controlling for confounds.

observational · Sample size: 130152

Lifetime use of psychedelics (including mescaline) was not associated with increased serious psychological distress, mental health treatment, suicidal thoughts/plans/attempts, depression, or anxiety.

observational · Sample size: 135095

Regular peyote use in a religious setting was not associated with psychological or cognitive deficits compared to minimal substance users.

observational · Sample size: 61

Mescaline, like other hallucinogens, involves agonist activity at the serotonin 5-HT2A receptor, which mediates its neuropsychological effects.

theoretical

Potency of hallucinogens (including mescaline) in the mouse head-twitch response assay strongly correlates with human hallucinogenic potency, supporting translational relevance.

preclinical

Psychedelics can exacerbate pre-existing psychotic illness and may trigger psychosis in vulnerable individuals, but the magnitude of risk is inadequately quantified.

review

Lifetime mescaline/peyote use was associated with lower opioid use disorder severity, particularly in those with high mental health impairment.

observational · Sample size: 45133

Mescaline produced cerebellar-selective BOLD suppression and global hyperconnectivity, and disrupted sensory processing, distinguishing it from LSD and psilocybin.

preclinical

Unclear

Mescaline is the only phenethylamine classic psychedelic, with the lowest 5-HT2A affinity requiring high doses (hundreds of mg), and clinical evidence is the weakest strand with no adequate RCT as of 2026.

review

Abuse of mescaline and its analogues has shown a gradual increase in recent years, and the paper reviews their pharmacological, toxicological, and detection aspects.

review

Points of agreement

  • Mescaline is a 5-HT2A receptor agonist and a classic psychedelic.
  • Large population studies find no association between lifetime mescaline use and mental health problems.
  • Long-term religious peyote use is not associated with psychological or cognitive deficits.
  • Mescaline can trigger psychosis in vulnerable individuals, but the risk magnitude is not well quantified.

Conflicts

  • One study found mescaline/peyote use associated with lower opioid use disorder severity, while other psychedelics (LSD/psilocybin/MDMA/DMT) were associated with higher severity.
  • Preclinical data show mescaline has distinct neuroimaging effects (cerebellar suppression) compared to LSD and psilocybin, but human comparative data are lacking.

Gaps

  • No adequate randomized controlled trials on mescaline exist as of 2026.
  • The risk of psychosis in vulnerable individuals is not adequately quantified.
  • Durability of effects and long-term outcomes beyond 12 months are not studied.
  • Most studies rely on self-report or observational designs; blinding is difficult.
  • Comparative studies between mescaline and other psychedelics in humans are lacking.
  • Dose-response relationships and optimal therapeutic dosing are not established.
Browse these studies in the library
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Mescaline, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Mescaline or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

1,002 articles · 145 from the last two years · 3,610,503 participants across 135 studies reporting sample size

Common study designs

review 149 systematic review 31 experimental study 76 historical analysis 49 theoretical or philosophical paper 62

magnetismo del peyote

Revista de Arqueología Americana • July 10, 2026 • Stacy B. Schaefer

Peyote (Lophophora williamsii) is a psychoactive cactus central to religious beliefs, healing practices, and transformative experiences among Indigenous peoples of Mexico and North America. The Wixárika (Huichol) have the longest known continuous use, while the Native American Church's practices in the US and parts of Canada developed more recently. This article reviews peyote's botany, chemistry, medicinal qualities, ecology, archaeology, history, and religious practices, presenting Indigenous knowledge, rituals, and adaptation to change. It concludes by discussing the alarming scarcity of peyote and conservation efforts to protect the plant's future.

Epigenetic landscapes of classical psychedelics and ketamine: molecular mechanisms of long-lasting neuromodulation

Molecular Psychiatry • July 10, 2026 • Cong Lin, Xiaohui Wang

Classic psychedelics like LSD, psilocybin, DMT, and mescaline, as well as the antidepressant ketamine, can cause lasting changes in brain function and behavior beyond their immediate effects. This review examines how these substances may influence epigenetic regulation—changes in gene activity that do not alter the DNA sequence itself—through mechanisms such as DNA methylation, histone modifications, and non-coding RNA dynamics. The authors propose that psychedelics also affect metabolic pathways, altering the availability of key molecules like acetyl-CoA and SAM, which in turn may impact gene expression and synaptic connectivity. Understanding these processes could help explain how short-term psychedelic exposure leads to sustained therapeutic benefits and guide the development of new treatments for neuropsychiatric conditions.

Maria Sabina-Die enteignete Heilerin / Vier Enteignungen, ein Muster

Zenodo (CERN European Organization for Nuclear Research) • July 8, 2026 • Schüller Thomas

Two works examine the appropriation of Indigenous healing practices. The first, 'Die enteignete Heilerin' (The Expropriated Healer), focuses on the Mazatec shaman Maria Sabina, whose use of psilocybin mushrooms was co-opted by outsiders. The second, 'Vier Enteignungen, ein Muster' (Four Expropriations, One Pattern), compares the appropriation of peyote, ayahuasca, salvia, and iboga, arguing that a common pattern of colonial and capitalist expropriation underlies these cases.

Der gezüchtete psychoaktive Pilz als Fall der Zugangs-Reorganisation — mit dem komparativen Fall des Peyote.** Transdisziplinäre Monografie (Ausbaustufe). Zweisprachig **DE + EN**

Zenodo (CERN European Organization for Nuclear Research) • July 1, 2026 • Schüller Thomas

A transdisciplinary monograph examines the cultivated psychoactive mushroom as a case of access reorganization, comparing it with peyote. The work argues that the regulation and cultural framing of these substances reshape who can access them and under what conditions, thereby reorganizing social and legal boundaries. The analysis draws on psychoanalysis and social critique to explore themes of closure, the fall of man, and therapeutic applications. The author presents this as a theoretical and philosophical paper, not an empirical study, and offers a bilingual (German and English) account funded privately and licensed under Creative Commons.

DMT und Ayahuasca / DMT and Ayahuasca

Zenodo (CERN European Organization for Nuclear Research) • July 1, 2026 • Schüller Thomas

DMT is the fourth classical psychedelic in a series and has five distinguishing features: oral inactivity without an MAO inhibitor; ultra-short duration (minutes) when smoked or injected; ayahuasca as a plant combination (DMT source plus β-carboline MAOI); endogenous occurrence in mammals; and the unique religious legal ruling Gonzales v. O Centro (2006). Chemically, DMT is a tryptamine (like psilocybin and LSD), contrasting with the phenethylamine mescaline. This bilingual full work provides a transdisciplinary scientific overview of DMT and ayahuasca across eight disciplines, with explicit labeling of levels of certainty (confirmed / probable / open).

Meskalin / Mescaline

Zenodo (CERN European Organization for Nuclear Research) • July 1, 2026 • Schüller Thomas

Mescaline is the only phenethylamine among the classic psychedelics, with the lowest affinity for the 5-HT2A receptor, requiring the highest doses (hundreds of milligrams) and producing a dose-dependent duration of 6.4 to 14 hours. Clinical research is the weakest strand: as of 2026, no adequate randomized controlled trial exists. In the ecologically bound case of peyote, the logic of dispossession reverses compared to synthetic substances like LSD and psilocybin. The work elevates Discipline 8 (Law/Society) to address peyote conservation (IUCN 'vulnerable') and Indigenous rights (Native American Church, AIRFA 1994) as a standalone discipline.

The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review

Journal of Psychopharmacology • June 26, 2026 • Flavia Giaffone de Paiva Ferreira, João Ariel Bonar Fernandes, Renato Filev et al.

A scoping review categorized psychosocial protocols used in psychedelic research for mental health treatment. Seven categories were defined, reflecting distinct emphases on the substance, participant, research team, and sociocultural context. Although limited reporting and heterogeneity remain methodological challenges, the proposed parameters suggest a shared language to describe, compare, and examine psychosocial protocols across studies, reducing conceptual uncertainty. The review may facilitate research decision-making and support structured, replicable study designs while allowing flexibility for individualized and culturally responsive care. Explicitly defining the intended purpose of psychosocial protocols could improve transparent reporting and evaluation.

The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential.

Journal of psychopharmacology (Oxford, England) • June 25, 2026 • Pavan S Brar, Rebecca B Price, Stephen Ross et al.

Psychedelic compounds like psilocybin and LSD are being studied again as potential treatments, but research usually excludes people at risk for psychosis. This narrative review examines the historical and theoretical links between psychedelics and schizophrenia spectrum disorders (SSDs), including the psychotomimetic hypothesis. The authors compare the phenomenological experiences induced by psychedelics with those of SSDs, finding both overlap and important qualitative differences that challenge a simple equivalence. They review neural mechanisms involving serotonin, dopamine, and glutamate. Clinical evidence shows psychedelics can worsen existing psychotic illness and may trigger psychosis in vulnerable individuals, though the risk magnitude is not well quantified. The authors suggest potential therapeutic applications for carefully selected symptoms in stable patients using low-dose, controlled approaches and provide recommendations for managing psychosis-related risk.

Chemical ecology and convergent evolution of natural hallucinogens: From ecological defense to conserved neural targets

Proceedings of the National Academy of Sciences • June 24, 2026 • Yibo Wang, H Wang, C T Lin et al.

Natural hallucinogenic compounds like mescaline and psilocybin evolved independently across plants, fungi, and animals through a 'building-block' biosynthetic logic that repurposes primary metabolism. These molecules likely function as defensive agents or manipulators of herbivore and pollinator behavior, not primarily for human psychoactivity. Endogenous mammalian tryptamines appear to serve cytoprotective and stress-response roles via sigma-1 receptors, not hallucinogenic functions. Across kingdoms, these compounds converge on conserved neural targets such as serotonergic systems, making human psychoactivity an evolutionary by-product of molecules selected for ecological interactions with animals sharing deeply conserved receptor architectures.

Micro-Messiahs and the Revolutionary Dynamics of Psychedelic Diffusion

Religions • June 24, 2026 • Leor Roseman

Prophetic or messianic states of consciousness can be charged with moral urgency and become active, historical, and political. The paper examines psychedelic micro-messianic phenomenology and revolutionary dynamics through three historical figures: Allen Ginsberg (LSD), Master Irineu (Daime/ayahuasca), and John Wilson/Moonhead (peyote). In moments of tension and uncertainty, psychedelics can catalyze micro-messianic movements that diffuse these substances into new situations. A revelatory event motivates the subject to spread the substance and practice, creating a movement that eventually becomes routinized or inverted, then stabilizes into a new status quo from which another revelatory event may arise. The analysis draws on Weber, Wallace, Kuhn, Taves, Whitehouse, Rogers, Badiou, and others to show how psychedelic insights and actions intertwine, with revelations seeking to ripple outward into movements.

Clinical trials

All Mescaline trials →